Business
- Business
Synaffix Sees Competitive Early In Vivo Data from ADCs Based on Proprietary Exatecan Linker-Payload
Amsterdam, Netherlands: In vivo efficacy on a par with gold standard deruxtecan-based ADCs Poster to be presented at World ADC meeting on 17 September 2020 Synaffix B.V., a biotechnology company enabling antibody-drug conjugates (ADCs) with…
Read More » -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-